All In Biotech

Drug Trial Radar · NCT07290569

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Oct 21, 2026

Study completion Dec 2028

Sponsor

Lead sponsor
Oruka Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • ORKA-001Drug

    ORKA-001 administered by subcutaneous (SC) injection

  • PlaceboOther

    Placebo administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Time frame: Week 16

Locations

36 sites in 4 countries. Site status is shown where the registry gives one.

  • Oruka Therapeutics Investigative Site

    Phoenix, Arizona

  • Oruka Therapeutics Investigative Site

    North Little Rock, Arkansas

  • Oruka Therapeutics Investigative Site

    Los Angeles, California

  • Oruka Therapeutics Investigative Site

    Los Angeles, California

  • Oruka Therapeutics Investigative Site

    San Diego, California

  • Oruka Therapeutics Investigative Site

    Miami, Florida

  • Oruka Therapeutics Investigative Site

    Rolling Meadows, Illinois

  • Oruka Therapeutics Investigative Site

    Plainfield, Indiana

  • Oruka Therapeutics Investigative Site

    Rockville, Maryland

  • Oruka Therapeutics Investigative Site

    Kew Gardens, New York

  • Oruka Therapeutics Investigative Site

    Chapel Hill, North Carolina

  • Oruka Therapeutics Investigative Site

    Cleveland, Ohio

  • Oruka Therapeutics Investigative Site

    Mason, Ohio

  • Oruka Therapeutics Investigative Site

    Portland, Oregon

  • Oruka Therapeutics Investigative Site

    Portland, Oregon

  • Oruka Therapeutics Investigative Site

    Philadelphia, Pennsylvania

  • Oruka Therapeutics Investigative Site

    Frisco, Texas

  • Oruka Therapeutics Investigative Site

    Houston, Texas

  • Oruka Therapeutics Investigative Site

    Webster, Texas

  • Oruka Therapeutics Investigative Site

    Norfolk, Virginia

  • Oruka Therapeutics Investigative Site

    Surrey, British Columbia, Canada

  • Oruka Therapeutics Investigative Site

    Surrey, British Columbia, Canada

  • Oruka Therapeutics Investigative Site

    Fredericton, New Brunswick, Canada

  • Oruka Therapeutics Investigative Site

    Ajax, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Markham, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Peterborough, Ontario, Canada

  • Oruka Therapeutics Investigative Site

    Montreal, Quebec, Canada

  • Oruka Therapeutics Investigative Site

    Québec, Quebec, Canada

  • Oruka Therapeutics Investigative Site

    Heidelberg, Baden-Wuerrtemberg, Germany

  • Oruka Therapeutics Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Oruka Therapeutics Investigative Site

    Bad Bentheim, Lower Saxony, Germany

  • Oruka Therapeutics Investigative Site

    Kiel, Schleswig-Holstein, Germany

  • Oruka Therapeutics Investigative Site

    Badalona, Barcelona, Spain

  • Oruka Therapeutics Investigative Site

    Barcelona, Barcelona, Spain

  • Oruka Therapeutics Investigative Site

    Madrid, Madrid, Spain

  • Oruka Therapeutics Investigative Site

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.